Therapy and Outcome Prediction using Urothelial Carcinoma orgANoids (TOUCAN)

Aim 1: Establish PDOs from noninvasive urothelial carcinoma specimens from transurethral resection of bladder tumor, cystectomy, or nephroureterectomy.

Aim 2: Perform cell viability chemosensitivity assays PDOs using single and multi-agent chemotherapeutic regimens. Correlate in vitro PDO treatment response with in vivo oncologic outcomes and response.

Aim 3: Characterize biomarker (immunohistochemical, molecular, and multiclonal genetic) heterogeneity of PDOs. Correlate biomarker findings with oncologic outcomes and response.

Aim 4: Identify novel therapeutic treatments based on PDO biomarker characterization (precision medicine) and chemosensitivity assays (testing novel combinations).

For further information about clinical trials, please contact us at 732-235-7356.